US › Healthcare

Pyxis Oncology Inc (PYXS)

US · Healthcare · Biotechnology

$1.68-6.67%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-25.3M

EPS

$-0.40

EPS estimate

$-0.34

EPS came in at -0.40 against a street estimate of -0.34 — a miss of 17.6%.

Key statistics

Market cap

$213.8M

Forward P/E

0.0

P/B

24.42

Book value

$0.18

EPS (TTM)

$-1.35

52-week high

$5.55

52-week low

$1.03

50-day MA

$3.01

200-day MA

$2.14

Beta

1.38

Analyst view

Analysts rate Pyxis Oncology Inc a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $8.67.

Shareholding

Insiders

9.47%

Institutions

39.54%

Largest institutional holders

Fund	Stake
GordonMD Global Investments LP	15.99%
Pfizer Inc	11.22%
LAURION CAPITAL MANAGEMENT LP	7.82%
Vanguard Capital Management, LLC	3.31%
Atle Fund Management AB	1.54%
683 Capital Management LLC	1.43%
BlackRock Inc	1.38%
Palo Alto Investors, LLC	1.38%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pyxis Oncology Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.